Live
- Italian envoy Baroli hoping to strengthen ties with India through football
- CPI-M revokes suspension of Bengal party leader accused of sexual harassment
- Rachakonda Commissioner Emphasizes Health and Education at Uniform Diet Launch
- BJP leader visits late ASI Surendra Singh in Rajasthan, assures full govt support
- PM Modi tears into Gandhi family for its habit of amending Constitution
- Young Kabaddi Player Dies of Heart Attack During Match in Mandya
- Exciting Return of Santosh Trophy Football Tournament Kicks Off in Hyderabad
- Head Constable Dies by Suicide, Cites harssament by wife and inlaws
- Delhi BJP claims AAP govt will never pay women allowance like in Punjab
- India is 'Mother of Democracy': PM Modi
MSN initiates phase III trials of Molnupiravir
MSN Laboratories Pvt. Ltd. (MSN) on Tuesday announced it is initiating phase III clinical trials of Molnupiravir capsules for the treatment of Covid-19 in India.
Hyderabad : MSN Laboratories Pvt. Ltd. (MSN) on Tuesday announced it is initiating phase III clinical trials of Molnupiravir capsules for the treatment of Covid-19 in India.
MSN received clinical trial approval from the Drug Controller General of India on May 19 to perform Molnupiravir capsules' efficacy and safety study on mild to moderate Covid-19 patients.
MSN will start its clinical trials in more than 40 sites across India and the first dosing is expected to begin soon. The clinical trials will be performed on more than 2,400 subjects suffering from mild to moderate Covid-19.
Molnupiravir is an experimental drug having antiviral properties and is currently under clinical stage study for Covid treatment. The MSN R&D team has developed both the API and formulation. It is expecting to soon launch the drug after successful conclusion of clinical study followed by regulatory approval.
The firm claimed to be the front-runner in introducing various drugs in the treatment of Covid-19 and its complications,
Last week it announced the launch of Posaone (Posacanazole) in the treatment of black fungus.
As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg and 800mg, Oselow (Oseltamivir) as 75 mg capsules and licensed Baridoz (Baricitinib) recently with Eli Lilly.
